美药厂开始新冠与流感混合疫苗临床试验

美国生技药厂诺瓦瓦克斯（Novavax）今天宣布，旗下由流感疫苗和COVID-19疫苗结合而成的新疫苗NanoFlu/NVX-CoV2373，已展开初期临床试验。

路透社报道，诺瓦瓦克斯先前指出，NanoFlu/NVX-CoV2373的临床前研究显示，这支疫苗不仅对于A型和B型流感能引起很强的免疫反应，对COVID-19（2019冠状病毒疾病）的SARS-CoV-2病毒也能产生防护力。

Vaccine-maker Novavax kicks off trial for combined Covid-19/flu jab - https://t.co/vRNDpIpI8s -
American vaccine-maker Novavax has started its early stage trial of a vaccine which combines an as-yet-unapproved Covid-19 shot with the company’s NanoFlu influenza jab.
... pic.twitter.com/UkKjeKwvAJ

— kashco.co.uk (@Kashco_co_uk) September 8, 2021